Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.47 |
| ▸ | EP300 | Q09472 | 2/20 | 0.45 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20159910 | 0.87 | NPC1 (0.39) | BRD4 | |
| SCHEMBL20160077 | 0.79 | BRD4 (0.49) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL20159924 | 0.79 | BRPF1 (0.46) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL20159868 | 0.79 | BRD9 (0.51) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL20159926 | 0.78 | BRPF1 (0.55) | BRD4EP300BRD2BRDT | |
| SCHEMBL20160107 | 0.77 | BRD4 (0.48) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL20160303 | 0.75 | BRD4 (0.58) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL20160053 | 0.74 | BRD4 (0.53) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL20160261 | 0.74 | BRD4 (0.58) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL20159846 | 0.73 | BRD4 (0.51) | BRD4EP300BRD2ADORA2BTSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018086585-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATIONS THEREOF | 山东罗欣药业集团股份有限公司 | 2018-05-17 | — | — | WO | disclosed |